Senior Research Associate, Molecular and Cellular Biology
See more jobs from Flagship Pioneeringalmost 3 years old
Company Summary:
What if…you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies in order to transform health care and sustainability?
Apriori Bio is an early-stage biotechnology company with an ambitious and exciting mission: to lay the foundation for Global Pathogen Shield™ protective interventions that that can neutralize a wide range of the most dangerous and rapidly evolving infectious pathogen threats. The company is developing a revolutionary approach to this challenge and recruiting a team of top-tier scientists to build what it believes will be a powerful, first-in-category R&D platform.
Apriori Bio is a product of Flagship Pioneering’s venture creation engine, which has also given rise to companies such as Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), and Editas Medicines (NASDAQ: EDIT). Since Flagship’s founding in 2000, the firm has originated and fostered the development of more than 100 scientific ventures, resulting in over $34 billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.
Position Summary:
We are seeking a highly motivated, collaborative, and detail-oriented research associate to join our quickly growing team at the interface of virology, functional genomics, and drug/vaccine design. This is an excellent opportunity for a researcher with lentiviral and/or cell culture experience to build additional expertise in cutting-edge virus and cell-based screening platforms. Technical responsibilities will include producing and characterizing lentivirus, generating and maintaining stable cell lines, and general cell culture. Additionally, there will be opportunities to gain or augment expertise in high-throughput molecular biology and next generation sequencing. This individual will join a dynamic, rapidly growing, and highly collaborative team where attention to detail and independent problem solving will be critical to success.
Key Responsibilities:
- Collaborate with a team of scientists and research associates to design and execute well-controlled experiments lentiviral and mammalian cell culture experiments
- Analyze data promptly to clearly depict and communicate results
- Participate on multi-disciplinary teams and communicate results (i.e., presentations, writing reports).
- Maintain a detailed and up-to-date electronic laboratory notebook
- Maintain detailed organization systems for samples and reagents from complex experimental pipelines
Basic Qualifications:
- M.S. or B.S. in Biology, Molecular Biology, Biochemistry, Virology, Immunology, or related field with 2+ years of research experience
- Strong hands-on experience in mammalian cell culture, virus or lentivirus work, flow cytometry, and/or molecular biology
- Stellar work ethic and a passion for benchwork
- A collaborative, team player and good lab citizen
- Strong organizational and record-keeping skills
- Effective and proactive communication
Preferred Qualifications:
- Experience or knowledge of the following skills are a plus but not necessary:
- Producing and/or characterizing lentiviruses and associated techniques (cloning, transfection, qPCR, ELISAs, functional assays)
- Stable cell line generation and flow cytometry
- Virology and/or antibody binding and neutralization assays
- High-throughput screening systems, functional genomics, or next generation sequencing
More About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $50B in aggregate value. To date, Flagship has deployed over $2.2B in capital toward the founding and growth of its pioneering companies alongside more than $18B of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ: SGTX).